Toll Free : + 1-888-961-4454 | US : +1 (917) 444-1262 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
The global blood stream infection testing market size is predicted to be valued at $10,540.8 million by 2030, surging from $5,173.1 million in 2021, at a healthy CAGR of 8.3%.
Businesses and economic activity around the world have been severely affected by the COVID-19 pandemic, which started in China. Due to the low or non-existence of medical facilities/treatment centers, COVID-19 is anticipated to have a positive effect on the market of blood stream infection testing. Governments of various countries across the world are recommending delaying or postponing unnecessary medical and surgical operations to relieve pressure on the healthcare system and minimize the spread of disease.
Global industrial and construction operations have been hampered by the COVID-19 outbreak. Manufacturers of blood stream infection testing kit are having trouble keeping up with changing raw material requirements and further logistical constraints faced due to COVID-19 pandemic. Several manufacturers encountered circumstances when demand for Blood Stream testing kit and reagent was far more than supply. As a result, it was difficult for certain laboratories to continue providing testing. The market for blood stream infection testing market growth was harmed as a result.
Any bacterial, fungal, or some other sort of infection found in the blood is known as a Blood Stream infection. Once the pathogen enters the blood stream of any part of the body, the infection risk is developed and if untreated can lead to sepsis. Thus it increases risk to develop severe infection or sepsis which causes a significant danger to human health, and declining hygienic conditions promotes spread of several infectious diseases. Blood stream infection testing is used to identify the bacteria or other organisms that cause blood infections which is expected to drive the blood infection testing market opportunity.
Blood Stream infections are challenging to self-diagnose due to their widespread symptoms, such as chills, a cold, fever, diarrhea, and vomiting. With these symptoms, health specialist can order blood work for further analyzing the infection. Thus this factor is expected to stimulate the market expansion. The blood stream infection tester monitors microorganisms for signs of antibiotic resistance. Sepsis can also be identified using Blood Stream infection testing kit. .
Over the course of period, a high demand for technically advanced diagnostic tests, awareness regarding cleanliness, diagnosis rates, and unhealthy lifestyles leading to weaker immunity will increase chances of infection and are anticipated to drive blood stream infection testing market trend expansion.
The blood stream infection testing market, however, may be hampered by the strict regulatory environment around diagnostic techniques such as laboratories require the approval from specific authority for commercial blood testing. For instance, General Laboratories in India requires approval from Indian Council of Medical Research (ICMR) for commercializing testing kit and lab facilities.
Additionally, rising awareness regarding chronic illnesses such as cancer, HIV, and pneumonia that call for blood testing at regular intervals is anticipated to fuel the market expansion. The blood stream infection testing market is developing due to innovations, investments in research and development, and mergers and acquisitions of the major players.
The global blood stream infection testing market based on product, technique, technology, end-user, and region.
Product:
The product segment is further classified into instruments, consumables, and software & services. Among these, the consumables sub-segment is anticipated to have dominant market share and generate a revenue of $8,505.3 million by 2030, increasing from $4,119.4 million in 2021. For drawing of blood from vein, the consumables used are syringes, needles, test tubes, bandages, cotton, alcohol swabs, bandages, and others. The rise in number of sepsis cases is fueling the blood stream infection testing, which is anticipated to drive this sub-segment.
Technique:
The technique segment is divided into conventional and automated. The automated sub-segment is expected to show fastest growth in Blood Stream infection testing market and generate a revenue of $3,280.1 million by 2030, with an increase from $1,504 million in 2021. The automated instruments such as Polymerase Chain Reaction (PCR), microarray, and peptide nucleic acid hybridization techniques are in demand, as they are more efficient and produce consistent results in less time. The results produced with this technique are more accurate and error free. This factor is expected to boost demand for automated techniques in near future.
Technology:
The technology segment is further divided into culture-based, molecular, and proteomic. The culture-based sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $6,092.1 million by 2030, with an increase from $3,123.1 million in 2021. Blood culture tests are used to detect bacterial infections that spread in to Blood Stream such as meningitis, pneumonia, and sepsis. They are also capable of detecting fungal and mycobacterium infections. These factors are expected to drive demand for culture-based technology in the blood stream infection testing market.
Application:
The application segment is further classified into bacterial, fungal, and mycobacterial. The bacterial sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,776.6 million by 2030, with an increase from $2,709.3 million in 2021. The bacterial testing for salmonella, listeria, E.coli, and campylobacter are the most common bacterial infection caused by food. Sedentary lifestyle and increased fast food consumption can lead to immune system dysfunction which increases bacterial infection susceptibility. Thus increase in number of bacterial infections cases is expected to drive this sub-segment growth.
End-user:
The end-user segment is further divided into hospitals, independent diagnostics centers, and others. The hospitals sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,247.1 million by 2030, with an increase from $2,665.6 million in 2021. High rates of pneumonia, cancer, wounds cases, increased hygiene awareness, increased healthcare awareness among population, and improvement in healthcare infrastructure in various countries such as India, China, and South Africa is projected to drive the global blood stream infection testing market.
Region:
The Blood Stream infection testing market outlook in North America region is projected to be dominant in market. North America generated a revenue of $2,084.8 million in 2021 and is projected to reach up to $4,067.7 million by 2030. The climate change has been affecting the human health. Temperature, humidity, and rainfall patterns are all meteorological elements that influence the intensity of infectious disease transmission. Population increase, urbanization, immigration, changes in land use and agricultural methods, deforestation, international travel, and a breakdown in public health systems have all played a major role in the recent comeback of infectious illnesses., Changes in ecological conditions and processes caused by temperature and precipitation fluctuations have an impact on infectious pathogen transmission, habitat, hosts, and pathogen characteristics. The change in ecological conditions have direct effect on water, land, plant, and air. Due to this factor prevalence rate of infection is increasing and it will drive the blood stream infection testing market demand in the North America region.
Some of the leading players in the global blood stream infection testing market are
Thermo Fisher, leading American based laboratory instruments, reagents manufacturer, and supplier announced partnership with the Mayo Clinic, a non-profit American academic medical organization in 2021, to speed up development and implementation of more precise and personalized diagnostics for blood-based cancers.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization